Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bronchioloalveolar Carcinoma: Not as Easy as “BAC”

Bronchioloalveolar Carcinoma: Not as Easy as “BAC” EDITORIAL Bronchioloalveolar Carcinoma: Not as Easy as “BAC” Howard L. West, MD,* and David H. Garfield, MD† n this issue, Cadranel et al. on behalf of the Intergroupe Francophone de Cance ´rologie IThoracique (IFCT) describe their experience of administering the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib as single-agent, first-line treatment to 88 patients with advanced bronchioloalveolar carcinoma (BAC) or adeno- 2,3 carcinoma with BAC features (IFCT-0401). Similar to other studies in this setting, the authors note its significant activity, but this work also highlights in a clinical report the highly clinically relevant variable of BAC subtype. Mucinous BAC (M BAC) arises from mucinous metaplasia of bronchiolar cells and 4,5 demonstrates strong intra- and extracellular mucosecretion. This form is more often associated with aerogenous spread, advanced disease, bronchorrhea, and a relatively rapid disease course. In contrast, nonmucinous BAC (NM BAC) can arise from either of two similar terminal cell types that are often detected in the same tumor: Clara cells and type II pneumocytes. NM BAC is most often detected at an early and resectable stage, is typically asymptomatic for a prolonged period, and its course is more likely to be indolent. Although the NM BAC http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Bronchioloalveolar Carcinoma: Not as Easy as “BAC”

Garfield, David H.
Journal of Thoracic Oncology , Volume 4 (9) – Sep 1, 2009
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/bronchioloalveolar-carcinoma-colon-not-as-easy-as-ldquo-bac-rdquo-nt02BBI3B2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181b6ebda
pmid
19704334
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Bronchioloalveolar Carcinoma: Not as Easy as “BAC” Howard L. West, MD,* and David H. Garfield, MD† n this issue, Cadranel et al. on behalf of the Intergroupe Francophone de Cance ´rologie IThoracique (IFCT) describe their experience of administering the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib as single-agent, first-line treatment to 88 patients with advanced bronchioloalveolar carcinoma (BAC) or adeno- 2,3 carcinoma with BAC features (IFCT-0401). Similar to other studies in this setting, the authors note its significant activity, but this work also highlights in a clinical report the highly clinically relevant variable of BAC subtype. Mucinous BAC (M BAC) arises from mucinous metaplasia of bronchiolar cells and 4,5 demonstrates strong intra- and extracellular mucosecretion. This form is more often associated with aerogenous spread, advanced disease, bronchorrhea, and a relatively rapid disease course. In contrast, nonmucinous BAC (NM BAC) can arise from either of two similar terminal cell types that are often detected in the same tumor: Clara cells and type II pneumocytes. NM BAC is most often detected at an early and resectable stage, is typically asymptomatic for a prolonged period, and its course is more likely to be indolent. Although the NM BAC

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Sep 1, 2009

There are no references for this article.